PMC

A66 was administered QD×21 at 100 mg/kg of body weight or BID until day 16 at 75 mg/kg of body weight, and BEZ-235 was administered QD×21 at 15 mg/kg of body weight. (A) Relative mean tumour volume following treatment with A66 and BEZ-235. Using one-way ANOVA analysis, the significance of tumour shrinkage compared with controls was calculated at days 8,12, 16 and 20 and found to be significantly different in the following conditions; BID A66 day 8 (P<0.05), BID A66 day 12 (P<0.005), BID A66 day 12 (P<0.005), BID A66 day 16 (P<0.005), BID A66 day 20 (P<0.01), QD A66 day 16 (P<0.05) and QD A66 day 20 (P<0.05). (B) Bod yweight change from start of treatment in mice treated with A66 and BEZ-235. Values are means±S.E.M. for seven or eight mice per group.

Western blotting was used to determine the phosphorylation status of Akt/PKB, p70 S6 kinase (pS6RbP) and ERK in SK-OV-3 tumours from mice 1 and 6 h after a single dose of A66 (100 mg/kg of body weight) or the control vehicle (n=5).

Gaussian kernel and bandwidth of 1 m used (n = 1078). The section of severed woodland at the A66 site is shown. The gantry is located at distance 0 m (height marked by square), and the pre-construction commuting route at 10–15 m. ‘Unsafe’ crossing heights are located below the dashed line. The dotted line marked verge shows the decrease in verge height above the road from left to right.

Comparison of capsular structures of serotype 3 strain A66 and recovered pneumococci. Pneumococcal variants of strain A66 recovered from HEp-2 cells (B, E, and H) and A459 cells (C, F, and I) were devoid of any visible capsular material, whereas strain A66 exhibited a dense capsular layer (A, D, and G). These observations were made by using three different methods, conventional FESEM (A to C), cryo-FESEM (D to F), and analysis of ultrathin sections (G to I) after LRR fixation. Bars = 0.5 μm.